Scientific Online Resource System

Annual for Hospital Pharmacy

Health technology assessment of Ixekizumab for treatment of plaque psoriasis in Bulgaria

Dima Tsanova, Nadia Veleva, Toni Vekov, Jivko Kolev, Evgeni Grigorov


The aim of the study is to analyze the published data from health technology assessments for the treatment of plaque psoriasis (PS) conducted in other countries to model the costs and health benefits of ixekizumab compared to the therapeutic alternatives used in Bulgarian clinical practice. Indirect comparison through network meta-analysis includes ixekizumab, secukinumab, ustekinumab, adalimumab, etanercept, infliximab. The economic analysis used is cost-utility. The study concludes that Ixekizumab is a cost-effective treatment for patients with plaque psoriasis after failure with standard therapy in Bulgaria compared to ustekinumab, adalimumab and infliximab.


plaque psoriasis, ixekizumab, cost-utility, analysis, cost effectiveness

Full Text


Parisi R, Symmons DP, Griffiths CE et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013; 133(2):377-85.

Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007; 370(9583):272-84.

Samarasekera EJ, Sawyer L, Wonderling D, et al. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. Br J Dermatol. 2013; 168(5):954- 67.

Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016; 375(4):345-56.

Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015; 386(9993):541-51.

Johansson E, Svedbom A, Kumar G et al. Cost-Effectiveness Analysis of Ixekizumab vs. Secukinumab in Sequential Biologic Treatment of Psoriasis in the UK. Value Health, 2016; 19(7), A568.

Lee A, Gregory V, Gu Q, et al. Cost-effectiveness of secukinumab compared to current treatments for the treatment of moderate to severe plaque psoriasis in Canada ISPOR 20th Annual International Meeting Philadelphia, May, 2015, PSS19.

D`Ausilio A, Aiello A, Daniel F et al. A Cost-Effectiveness Analysis of Secukinumab 300 Mg Vs Current Therapies for The Treatment of Moderate to Severe Plaque Psoriasis In Italy. Value Health. 2015;18(7):A424.

Klimes J, Mollon P, Graham C, et al. Cost-Effectiveness Analysis of Secukinumab Compared to Ustekinumab In The Treatment of Moderate to Severe Plaque Psoriasis In The Czech Republic. Value Health. 2015;18(7):A424.

Ruano J,Isla-Tejera B, Jimenez-Puya R, et al. Long-Term Cost- Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis. Dermatol Ther (Heidelb). 2013; 3(2): 131-142.

Knight C, Mauskopf J, Ekelund M, et al. Cost-Effectiveness of Treatment With Etanercept for Psoriasis in Sweden. Eur J Health Econ. 2011; 13 (2), 145-156.

Spandonaro F, Ayala F, Berardesca E, et al. The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy. BioDrugs. 2014; 28(3):285-95.

Riveros BS, Ziegelmann PK, Correr CJ. Cost-Effectivenessof Biologic Agentsinthe Treatmentof Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective. Value Health. 2014; 32(5):65-7 2.

Caporis X. Cost-effectiveness analysis of biologics in psoriasis, iHEA 2007, 6th World Congress: Explorations in Health Economics Paper, https: // = 993050.

Pan F, Brazier NC, Shear NH, et al. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective. Value Health. 2011;14(5):652-6.



Article Tools
Email this article (Login required)